

# Preliminary Results – CIRS VE phantom analysis

Ned Rouze, Yufeng Deng, Mark Palmeri,  
Kathy Nightingale

Phantoms provided by: Ted Lynch, CIRS

Clinical data – group SWS analysis presented  
in Palmeri et al, J. Hep, 2011.

Dispersion analysis of clinical data presented  
in: Nightingale et. al, IEEE UFFC IUS  
Proceedings 2013.

# F3 Human Liver




group SWS ratio: 1.35 (greater than 1 indicates dispersion)

Displacement

Velocity

2D FT

$\mu = 8.07$  kPa,  $\eta = 4.42$  Pas



Voigt model for  $c(\omega)$ ,  $\mu_1 =$  shear modulus  $\mu_2$ ,  $\eta =$  shear viscosity

$$c(\omega) = \sqrt{\frac{2(\mu_1^2 + \omega^2 \mu_2^2)}{\rho(\mu_1 + \sqrt{\mu_1^2 + \omega^2 \mu_2^2})}}$$

Nightingale et al Proceedings of IEEE UFFC IUS symposium, Prague, 2013.

# F1 Human Liver




group SWS ratio: 1.21

Displacement


Velocity

2D FT

$\mu = 1.84$  kPa,  $\eta = 0.88$  Pas



# Sample VE Phantoms vs. Human Liver



Voigt model dispersion fit to the 2D FT data for:

- our NAFLD patient data (black points)
- Best threshold (yellow point) with the largest AUROC for separating fibrosis stages  $\leq$  F2 from those  $\geq$  F3 in our NAFLD patient population
- CIRS E2117-X phantoms (x's and +'s)

To do: –Ship phantoms to Mayo for their analysis  
–Select two or three? recipes to use for phase 2...